Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 target price on the biotechnology company’s stock.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded up $0.55 during trading hours on Tuesday, hitting $4.96. The stock had a trading volume of 859,169 shares, compared to its average volume of 341,114. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $7.28. The stock has a market capitalization of $158.62 million, a price-to-earnings ratio of -5.72 and a beta of 3.92. The stock’s fifty day moving average is $4.33 and its two-hundred day moving average is $5.17.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. As a group, sell-side analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently bought and sold shares of the stock. Jump Financial LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter valued at $258,000. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics in the first quarter valued at approximately $40,000. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the period. Bank of New York Mellon Corp grew its stake in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the period. Finally, Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at $147,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.